[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"nt-pro-bnp\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:nt-pro-bnp":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,51],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":33,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":5},"100619382","population-based-atrial-fibrillation-screening-in-individuals-with-nt-probnp-above-median-in-the-troms-study-100619382",false,"NCT07343895","Population-based Atrial Fibrillation Screening in Individuals With NT-proBNP Above Median in the Tromsø Study","Atrial Fibrillation and Long Term ECG Monitoring of Heart Rhythm in the Tromsø Study","PAFS-Tromsø","Inclusion Criteria:\n\n* Age ≥40 years\n* NT-proBNP\\> median level\n* Informed consent for participation\n\nExclusion Criteria:\n\n* History of AF (self-reported)\n* Use of anticoagulation therapy\n* Pacemaker\u002FCRT device\n* No available smart phone",true,"ALL","40 Years",{"count":21,"type":22},4000,"ESTIMATED","INTERVENTIONAL",[25],"NA","The aim is to investigate whether screening with long-term ECG monitoring in individuals with elevated NT-proBNP leads to a lower incidence of ischeamic stroke and death from vascular causes. The project is a sub-study within the 8th wave of the population based Tromsø Study. Information on previous diseases, medication use, and risk factors is collected through questionnaires, blood samples, and measurements of height, weight, blood pressure, and ECG.\n\nA total of 4,000 individuals with NT-proBNP levels above the median, without previously known atrial fibrillation (AF) or ongoing anticoagulation therapy, will be randomized to either long-term heart rhythm monitoring (7 days) or a control group without long-term ECG monitoring (2,000 in each group). Individuals with AF in the intervention group will be offered anticoagulation therapy in accordance with current guidelines.\n\nThe intervention group and the control group will be compared with regards to incident stroke and death within a 6-year follow-up period. Information on endpoints and anticoagulation use will be obtained through linkage to national registries.",[28,29,30,31,32],"Atrial Fibrillation (AF)","Stroke","NT-pro-BNP","Cognitive Function and Well-Being","Heart Failure",[34,35,29,36,37,38,32],"ECG247","Atrial Fibrillation","NT-Pro-BNP","Cognitive decline","Life Quality","RECRUITING","2026-01-06",{"date":42,"type":43},"2026-01-15","ACTUAL",{"date":45,"type":43},"2025-10-24",{"date":47,"type":22},"2035-03-01",{"name":49,"class":50},"University Hospital of North Norway","OTHER",{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":18,"minAge":59,"maxAge":4,"enrollmentInfo":60,"targetDuration":62,"studyType":63,"phases":4,"briefSummary":64,"conditions":65,"keywords":70,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":5},"100593969","association-of-plasma-n-terminal-pro-brain-natriuretic-peptide-levels-with-the-burden-of-coronary-artery-disease-100593969","NCT07013344","Association of Plasma N-terminal Pro-Brain Natriuretic Peptide Levels With the Burden of Coronary Artery Disease","Association of Plasma N-terminal Pro-Brain Natriuretic Peptide Levels With the Burden of Coronary Artery Disease: Insights From a Real-World Cohort","BNP-CAD","Inclusion Criteria:\n\n* patient referred for elective coronary angiography due to suspected CAD.\n* NT-proBNP measurement during hospitalization\n\nExclusion Criteria:\n\n* heart failure\n* severe valvular disease\n* atrial fibrillation\n* severe chronic kidney disease (eGFR \\\u003C 30 mL\u002Fmin)\n* prior coronary artery bypass grafting\n* age over 80 years","18 Years",{"count":61,"type":22},800,"1 Day","OBSERVATIONAL","This study aim to investigate the association between plasma NT-proBNP levels and the presence, extent and severity of stenosis in patients with suspected coronary artery disease.",[66,67,68,69,30],"Chronic Coronary Syndrome","Chronic Coronary Total Occlusion","Coronary Arterial Disease (CAD)","Stable Chronic Angina",[30,68,71],"Chronic Coronary Syndrome (CCS)","2025-06-05",{"date":74,"type":43},"2025-06-10",{"date":76,"type":43},"2021-09-01",{"date":78,"type":22},"2025-07-31",{"name":80,"class":50},"IRCCS Ospedale San Raffaele"]